Pharmaceutical Executive
York, UK-Pharma companies have failed to prevent product counterfeiting, and experts warn that the industry-wide security body has no coordinated approach to help.
York, UK-Pharma companies have failed to prevent product counterfeiting, and experts warn that the industry-wide security body has no coordinated approach to help.
Counterfeiting prevention specialist Joe Hancock of Biocode says, because pharma companies focus on business issues such as satisfying regulators and bringing new pro-ducts to market, they pay little attention to the problem. The World Health Organization estimates counterfeiting costs the industry $16 billion a year in lost revenue, or 7 percent of global sales.
Hancock points to China, India, Africa, Asia Pacific, and South America as centers for counterfeit trade. He says fake medicines have been found in 28 countries, including the United States and the United Kingdom. Of 751 cases, 25 percent are from industrialized countries, 65 percent from developing countries, and 10 percent are unknown.
All products are at risk, says Hancock. But lifestyle products that are sold in high volume, such as Viagra, and high-value drugs often unavailable in developing countries are particularly vulnerable.
Hancock says counterfeiting requires little or no capital. Manufacturing can be done in developing-world sweatshops, and modern print technology makes it easy to copy packaging. Most counterfeits look like the genuine product but contain little or no active ingredient. Even worse, they can contain toxic substances used to make the product appear similar to the genuine article.
Biocode uses immunoassay technology to covertly code genuine products and packaging items, sometimes in combination with overt technologies such as holograms. It can encode manufacturing site information, batch ID, and authenticity into products at the production facility.
It uses field test kits, including scanner pen systems, which can identify counterfeits, ascertain if a product is in the correct country, and investigate the medicine's source.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.